$PALI
PALISADE BIO, INC. Stock $pali

$pali Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414047843 Filed on August 08, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$5.000K	$5.000K	$2.500K
YoY Change	100.0%	100.0%	-96.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.970M	$1.520M	$1.280M
YoY Change	15.2%	18.75%	56.1%
% of Gross Profit
Research & Development	$2.110M	$2.000M	$1.906M
YoY Change	14.21%	4.91%	19.25%
% of Gross Profit
Depreciation & Amortization	$80.00K	$90.00K	$50.00K
YoY Change	0.0%	80.0%	0.0%
% of Gross Profit
Operating Expenses	$4.112M	$3.516M	$3.238M
YoY Change	13.07%	8.59%	31.56%
Operating Profit	-$4.107M	-$3.511M	-$3.236M
YoY Change	13.01%	8.52%	35.76%
Interest Expense	$361.6K	$397.6K	$439.3K
YoY Change	-19.45%	-9.48%	72990.02%
% of Operating Profit
Other Income/Expense, Net	-$348.5K	-$3.240M	-$3.016M
YoY Change	-88.59%	7.43%	-43975.88%
Pretax Income	-$4.460M	-$6.750M	-$6.250M
YoY Change	-33.33%	8.0%	162.61%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$4.455M	-$6.751M	-$6.252M
YoY Change	-33.37%	7.99%	163.07%
Net Earnings / Revenue	-89104.74%	-135025.64%	-250065.2%
Basic Earnings Per Share
Diluted Earnings Per Share	-$74.33M	-$112.5M	-$156.3M
COMMON SHARES
Basic Shares Outstanding	86.84M shares	86.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.95M	$30.23M	$11.17M
YoY Change	64.33%	170.64%	339.76%
Cash & Equivalents	$11.95M	$15.23M	$11.17M
Short-Term Investments	$15.01M	$15.00M
Other Short-Term Assets	$750.0K	$590.0K	$810.0K
YoY Change	-18.48%	-27.16%	179.31%
Inventory
Prepaid Expenses	$409.1K	$196.2K	$156.6K
Receivables	$32.76K	$24.47K	$56.76K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$27.73M	$30.84M	$11.97M
YoY Change	60.05%	157.64%	323.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$301.3K	$310.1K	$189.8K
YoY Change	18.82%	63.34%	-29.7%
Goodwill
YoY Change
Intangibles	$1.246M	$1.247M	$984.9K
YoY Change	18.85%	26.66%
Long-Term Investments
YoY Change
Other Assets	$57.72K	$58.86K	$59.57K
YoY Change	-11.01%	-1.19%	-0.72%
Total Long-Term Assets	$1.709M	$1.786M	$1.827M
YoY Change	-6.98%	-2.23%	61.67%
TOTAL ASSETS
Total Short-Term Assets	$27.73M	$30.84M	$11.97M
Total Long-Term Assets	$1.709M	$1.786M	$1.827M
Total Assets	$29.44M	$32.63M	$13.80M
YoY Change	53.62%	136.47%	248.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.440M	$2.030M	$810.0K
YoY Change	101.65%	150.62%	-29.57%
Accrued Expenses			$310.0K
YoY Change			-3.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.058M	$2.952M	$1.236M
YoY Change	53.99%	138.93%
Total Short-Term Liabilities	$5.705M	$4.991M	$3.006M
YoY Change	10.82%	66.03%	104.5%
LONG-TERM LIABILITIES
Long-Term Debt	$2.611M	$3.416M	$6.364M
YoY Change	-53.87%	-46.32%
Other Long-Term Liabilities	$220.0K	$190.0K	$60.00K
YoY Change	144.44%	216.67%
Total Long-Term Liabilities	$2.611M	$3.416M	$6.364M
YoY Change	-53.87%	-46.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.705M	$4.991M	$3.006M
Total Long-Term Liabilities	$2.611M	$3.416M	$6.364M
Total Liabilities	$8.539M	$8.600M	$9.425M
YoY Change	-21.65%	-8.76%	541.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$145.6M	-$141.1M	-$118.4M
YoY Change	16.33%	19.13%
Common Stock	$871.6K	$868.4K	$706.1K
YoY Change	13.69%	22.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.90M	$24.03M	$4.413M
YoY Change
Total Liabilities & Shareholders Equity	$29.44M	$32.63M	$13.80M
YoY Change	53.62%	136.47%	248.44%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$4.455M	-$6.751M	-$6.252M
YoY Change	-33.37%	7.99%	163.07%
Depreciation, Depletion And Amortization	$80.00K	$90.00K	$50.00K
YoY Change	0.0%	80.0%	0.0%
Cash From Operating Activities	-$3.110M	-$2.410M	-$3.360M
YoY Change	38.22%	-28.27%	37.7%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$170.0K	-$140.0K
YoY Change	-55.0%	21.43%	16.67%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$0.00
YoY Change
Cash From Investing Activities	-$100.0K	-$170.0K	-$140.0K
YoY Change	-50.0%	21.43%	16.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-90.00K	-530.0K	2.000M
YoY Change	-101.17%	-126.5%	-5100.0%
NET CHANGE
Cash From Operating Activities	-3.110M	-2.410M	-3.360M
Cash From Investing Activities	-100.0K	-170.0K	-140.0K
Cash From Financing Activities	-90.00K	-530.0K	2.000M
Net Change In Cash	-3.300M	-3.110M	-1.500M
YoY Change	-163.1%	107.33%	-42.31%
FREE CASH FLOW
Cash From Operating Activities	-$3.110M	-$2.410M	-$3.360M
Capital Expenditures	-$90.00K	-$170.0K	-$140.0K
Free Cash Flow	-$3.020M	-$2.240M	-$3.220M
YoY Change	47.32%	-30.43%	38.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	360848	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	58859	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64897	USD
CY2014Q2	us-gaap	Assets Assets	32628549	USD
CY2013Q4	us-gaap	Assets Assets	19413536	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2025694	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1662058	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2952333	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2763121	USD
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1417527	USD
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	15000000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24468	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10000	USD
CY2014Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	389297	USD
CY2013Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	507334	USD
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	196209	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	255733	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	30842430	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	17619119	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	310050	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	230971	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1247498	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1137701	USD
CY2014Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	169712	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13139	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	93426	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4991166	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5936132	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3415984	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4934210	USD
CY2014Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	192707	USD
CY2013Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	124995	USD
CY2014Q2	us-gaap	Liabilities Liabilities	8599857	USD
CY2013Q4	us-gaap	Liabilities Liabilities	10995337	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	868375	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	778860	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164250586	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136058135	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7241	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141096376	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	24028692	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32628549	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19413536	USD
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
	cur	Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents PolicyForMaximumMaturityDaysOfInvestmentsConsideredAsCashEquivalents	P90D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39700000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86837455	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77886031	shares
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8000000	USD
CY2013Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	2000000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.11	pure
CY2014Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.11	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-06-30
	cur	Debt Instrument Weighted Average Interest Rate DebtInstrumentWeightedAverageInterestRate	0.11	pure
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	7551000	USD
CY2013Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	300000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	541026	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18577207	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	513482	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	320063	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	274937	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18495689	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13090287	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	18495689	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.79
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.43
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.53
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.20
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.85
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.11
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.85
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24000710	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1301650	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	43774349	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	27656155	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	43774349	USD
CY2014Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	18495689	shares
	cur	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.69
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.16
CY2013Q1	cur	Warrants Issued During Period WarrantsIssuedDuringPeriod	258000	shares
CY2013Q1	cur	Class Of Warrant Or Right Exercise Price Of Warrants Issued ClassOfWarrantOrRightExercisePriceOfWarrantsIssued	1.25
CY2013Q1	us-gaap	Share Price SharePrice	1.25
CY2013Q1	cur	Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction StockIssuedDuringPeriodShareFromWarrantsInConjunctionWithDebtTransaction	1297607	shares
CY2013Q1	cur	Warrants And Shares Issued Value Net WarrantsAndSharesIssuedValueNet	323000	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	350650	shares
CY2013Q1	cur	Stock Issued During Period Share From Warrants Exercised StockIssuedDuringPeriodShareFromWarrantsExercised	258000	shares
CY2013Q1	cur	Warrants Expiration Date WarrantsExpirationDate	2020-03-31
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4704000	USD
	cur	Compensation Expenses Unvested Stock Option Term Period CompensationExpensesUnvestedStockOptionTermPeriod	P2Y6M
	cur	Compensation Expenses Unvested Restricted Stock Term Period CompensationExpensesUnvestedRestrictedStockTermPeriod	P8M12D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
	cur	Warrants Exercisable Years WarrantsExercisableYears	P5Y
CY2014Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	44200000	shares
	cur	Compensation Expenses Unvested Restricted Stockoutstanding Value CompensationExpensesUnvestedRestrictedStockoutstandingValue	70000	USD
	us-gaap	Revenues Revenues	105000	USD
	us-gaap	Revenues Revenues	9167	USD
CY2013Q2	us-gaap	Revenues Revenues	2500	USD
CY2014Q2	us-gaap	Revenues Revenues	5000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3654734	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3518779	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1906387	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1947558	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2477050	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5001307	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1281210	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1481948	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100598	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	177220	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	50505	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6127382	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86732	USD
	us-gaap	Operating Expenses OperatingExpenses	6232382	USD
	us-gaap	Operating Expenses OperatingExpenses	8697306	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	3238102	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	3516238	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8688139	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3235602	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3511238	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	26560	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	42140	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	16635	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	17422	USD
	us-gaap	Interest Expense InterestExpense	487528	USD
	us-gaap	Interest Expense InterestExpense	830357	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	439271	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	397616	USD
	cur	Warrant Modification Expense WarrantModificationExpense	3071942	USD
	cur	Warrant Modification Expense WarrantModificationExpense	3109850	USD
CY2013Q2	cur	Warrant Modification Expense WarrantModificationExpense	2405206	USD
CY2014Q2	cur	Warrant Modification Expense WarrantModificationExpense	3109850	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	181799	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	334133	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	188317	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Other Income OtherIncome	374	USD
	us-gaap	Other Income OtherIncome	250000	USD
CY2013Q2	us-gaap	Other Income OtherIncome	131	USD
CY2014Q2	us-gaap	Other Income OtherIncome	250000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3714335	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3982200	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3016028	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3240044	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9841717	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12670339	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-6251630	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6751282	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69591602	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86477797	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69864599	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87186586	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1134	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	130	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-9841717	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-12671473	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-6251630	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-6751152	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	239122	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	432108	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53422	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14468	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-44377	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-58444	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-684082	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	465579	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1219	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1256	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5420	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-6677	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5872297	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5124872	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	15000000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	232215	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	247602	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5392	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	145091	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-237607	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-15392693	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2397241	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1651216	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	133000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	19053534	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7551329	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	cur	Payment Of Employee Taxes On Stock Option Exercise PaymentOfEmployeeTaxesOnStockOptionExercise	0	USD
	cur	Payment Of Employee Taxes On Stock Option Exercise PaymentOfEmployeeTaxesOnStockOptionExercise	426212	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1425123	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	81362	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	81543	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9832208	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18904872	USD
	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	0	USD
	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-903	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3722304	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1613596	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7443773	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11166077	USD
	us-gaap	Interest Paid InterestPaid	175071	USD
	us-gaap	Interest Paid InterestPaid	398248	USD
	cur	Issuance Of Common Stock For Cashless Excercise Of Warrants IssuanceOfCommonStockForCashlessExcerciseOfWarrants	0	USD
	cur	Issuance Of Common Stock For Cashless Excercise Of Warrants IssuanceOfCommonStockForCashlessExcerciseOfWarrants	838213	USD
	cur	Issuance Of Common Stock For Cash Less Excercise Of Option IssuanceOfCommonStockForCashLessExcerciseOfOption	0	USD
	cur	Issuance Of Common Stock For Cash Less Excercise Of Option IssuanceOfCommonStockForCashLessExcerciseOfOption	366199	USD
	cur	Issuance Of Common Stock Related To Debt Issuance Fees IssuanceOfCommonStockRelatedToDebtIssuanceFees	396234	USD
	cur	Issuance Of Common Stock Related To Debt Issuance Fees IssuanceOfCommonStockRelatedToDebtIssuanceFees	0	USD
	cur	Issuance Of Warrants For Fees Related To Debt Issuance IssuanceOfWarrantsForFeesRelatedToDebtIssuance	452187	USD
	cur	Issuance Of Warrants For Fees Related To Debt Issuance IssuanceOfWarrantsForFeesRelatedToDebtIssuance	0	USD
CY2013Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.25
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5997	USD
	cur	Issuance Of Warrants For Vendor Services IssuanceOfWarrantsForVendorServices	143478	USD
	cur	Issuance Of Warrants For Vendor Services IssuanceOfWarrantsForVendorServices	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	35000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Neuralstem, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001357459
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	CUR
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86837455	shares
	cur	Class Of Warrant Or Right Expense Recognized ClassOfWarrantOrRightExpenseRecognized	3100000	USD
	cur	Increase Decrease In Common Stock Shares Authorized IncreaseDecreaseInCommonStockSharesAuthorized	150000000	shares

Files In Submission

Name	View Source	Status
0001144204-14-047843-index-headers.html	Edgar Link	pending
0001144204-14-047843-index.html	Edgar Link	pending
0001144204-14-047843.txt	Edgar Link	pending
0001144204-14-047843-xbrl.zip	Edgar Link	pending
cur-20140630.xml	Edgar Link	completed
cur-20140630.xsd	Edgar Link	pending
cur-20140630_cal.xml	Edgar Link	unprocessable
cur-20140630_def.xml	Edgar Link	unprocessable
cur-20140630_lab.xml	Edgar Link	unprocessable
cur-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v384729_10q.htm	Edgar Link	pending
v384729_ex3-01.htm	Edgar Link	pending
v384729_ex31-1.htm	Edgar Link	pending
v384729_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PALI
PALISADE BIO, INC. Stock $pali

2014 Q3 Form 10-Q Financial Statement

#000114420414047843 Filed on August 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI PALISADE BIO, INC. Stock $pali

2014 Q3 Form 10-Q Financial Statement

#000114420414047843 Filed on August 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI
PALISADE BIO, INC. Stock $pali